Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 12/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154941 | 0.86 | AAK1 (0.49) | AAK1STK17BSTK17ABRD4ROCK2 | |
| SCHEMBL17155025 | 0.76 | STK17B (0.55) | STK17BSTK17ABRD4CA12CA1 | |
| SCHEMBL31080085 | 0.76 | STK17B (0.55) | STK17BSTK17ABRD4CA12CA1 | |
| SCHEMBL18990566 | 0.75 | SUCNR1 (0.47) | STK17BSTK17ATTKCA12CA1 | |
| SCHEMBL18990569 | 0.75 | SUCNR1 (0.47) | STK17BSTK17ATTKCA12CA1 | |
| SCHEMBL29358317 | 0.75 | SUCNR1 (0.43) | STK17BSTK17ABRD4TTKCA12 | |
| SCHEMBL12289949 | 0.73 | UBE2M (0.39) | BRD4PIM1PIM2 | |
| SCHEMBL31401160 | 0.73 | POLB (0.48) | STK17BSTK17ABRD4DYRK1ACA12 | |
| SCHEMBL30129641 | 0.73 | CACNA1H (0.41) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL5457943 | 0.72 | STK17B (0.46) | STK17BSTK17ABRD4TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | AAK1 311/4885STK17B 1578/4885STK17A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.